Richard Marsden, Synairgen CEO
February 22, 2022 07:26 AM EST
R&D

Biotech shares evis­cer­at­ed in wake of Covid-19 flop

Amber Tong

When Southamp­ton, UK-based Synair­gen last up­dat­ed its in­vestors, CEO Richard Mars­den spot­light­ed the progress it’s mak­ing on the Phase III SPRINT­ER tri­al for the lead …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times